Anti-CD70 antibodies

A potential treatment for EBV+ CD70-expressing lymphomas

Bruce F. Israel, Margaret Gulley, Sandra Elmore, Silvano Ferrini, Wen Hai Feng, Shannon C. Kenney

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A monoclonal antibody (Rituximab) directed against the B-cell surface antigen, CD20, is increasingly used as a therapy for B-cell lymphomas. However, CD20 is expressed on all normal mature B cells and hence is not a specific tumor target. In contrast, CD70 is expressed on highly activated lymphocytes as well as on many B-cell and T-cell lymphomas but is not expressed on the great majority of B cells and T cells. In this report, we have explored the potential utility of anti-CD70 monoclonal antibodies for treatment of CD70+ EBV+ B-cell lymphomas. Using two Burkitt's lymphoma lines (Raji and Jijoye) that express surface CD70 and a CD70- Burkitt's lymphoma line (Akata), we show that two different monoclonal antibodies directed against human CD70 allow rabbit and human complement to kill EBV+ B cells in a CD70-dependent manner in vitro. In the absence of complement, neither anti-CD70 antibody induced in vitro killing of CD70+ cell lines. Importantly, i.p. injection of anti-CD70 antibodies also inhibited the growth of CD70+ Burkitt's lymphoma cells in severe combined immunodeficient mice but did not inhibit the growth of CD70- Burkitt's lymphoma cells. These results suggest that anti-CD70 antibodies may be useful for the treatment of CD70+ B-cell lymphomas.

Original languageEnglish
Pages (from-to)2037-2044
Number of pages8
JournalMolecular Cancer Therapeutics
Volume4
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Human Herpesvirus 4
Burkitt Lymphoma
Anti-Idiotypic Antibodies
Lymphoma
B-Lymphocytes
B-Cell Lymphoma
Monoclonal Antibodies
Therapeutics
SCID Mice
T-Cell Lymphoma
Surface Antigens
Growth
Lymphocytes
Rabbits
T-Lymphocytes
Cell Line
Injections
Neoplasms
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Israel, B. F., Gulley, M., Elmore, S., Ferrini, S., Feng, W. H., & Kenney, S. C. (2005). Anti-CD70 antibodies: A potential treatment for EBV+ CD70-expressing lymphomas. Molecular Cancer Therapeutics, 4(12), 2037-2044. https://doi.org/10.1158/1535-7163.MCT-05-0253

Anti-CD70 antibodies : A potential treatment for EBV+ CD70-expressing lymphomas. / Israel, Bruce F.; Gulley, Margaret; Elmore, Sandra; Ferrini, Silvano; Feng, Wen Hai; Kenney, Shannon C.

In: Molecular Cancer Therapeutics, Vol. 4, No. 12, 12.2005, p. 2037-2044.

Research output: Contribution to journalArticle

Israel, BF, Gulley, M, Elmore, S, Ferrini, S, Feng, WH & Kenney, SC 2005, 'Anti-CD70 antibodies: A potential treatment for EBV+ CD70-expressing lymphomas', Molecular Cancer Therapeutics, vol. 4, no. 12, pp. 2037-2044. https://doi.org/10.1158/1535-7163.MCT-05-0253
Israel, Bruce F. ; Gulley, Margaret ; Elmore, Sandra ; Ferrini, Silvano ; Feng, Wen Hai ; Kenney, Shannon C. / Anti-CD70 antibodies : A potential treatment for EBV+ CD70-expressing lymphomas. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 12. pp. 2037-2044.
@article{46d8f85dd1594c1b82452270ddaeb670,
title = "Anti-CD70 antibodies: A potential treatment for EBV+ CD70-expressing lymphomas",
abstract = "A monoclonal antibody (Rituximab) directed against the B-cell surface antigen, CD20, is increasingly used as a therapy for B-cell lymphomas. However, CD20 is expressed on all normal mature B cells and hence is not a specific tumor target. In contrast, CD70 is expressed on highly activated lymphocytes as well as on many B-cell and T-cell lymphomas but is not expressed on the great majority of B cells and T cells. In this report, we have explored the potential utility of anti-CD70 monoclonal antibodies for treatment of CD70+ EBV+ B-cell lymphomas. Using two Burkitt's lymphoma lines (Raji and Jijoye) that express surface CD70 and a CD70- Burkitt's lymphoma line (Akata), we show that two different monoclonal antibodies directed against human CD70 allow rabbit and human complement to kill EBV+ B cells in a CD70-dependent manner in vitro. In the absence of complement, neither anti-CD70 antibody induced in vitro killing of CD70+ cell lines. Importantly, i.p. injection of anti-CD70 antibodies also inhibited the growth of CD70+ Burkitt's lymphoma cells in severe combined immunodeficient mice but did not inhibit the growth of CD70- Burkitt's lymphoma cells. These results suggest that anti-CD70 antibodies may be useful for the treatment of CD70+ B-cell lymphomas.",
author = "Israel, {Bruce F.} and Margaret Gulley and Sandra Elmore and Silvano Ferrini and Feng, {Wen Hai} and Kenney, {Shannon C.}",
year = "2005",
month = "12",
doi = "10.1158/1535-7163.MCT-05-0253",
language = "English",
volume = "4",
pages = "2037--2044",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Anti-CD70 antibodies

T2 - A potential treatment for EBV+ CD70-expressing lymphomas

AU - Israel, Bruce F.

AU - Gulley, Margaret

AU - Elmore, Sandra

AU - Ferrini, Silvano

AU - Feng, Wen Hai

AU - Kenney, Shannon C.

PY - 2005/12

Y1 - 2005/12

N2 - A monoclonal antibody (Rituximab) directed against the B-cell surface antigen, CD20, is increasingly used as a therapy for B-cell lymphomas. However, CD20 is expressed on all normal mature B cells and hence is not a specific tumor target. In contrast, CD70 is expressed on highly activated lymphocytes as well as on many B-cell and T-cell lymphomas but is not expressed on the great majority of B cells and T cells. In this report, we have explored the potential utility of anti-CD70 monoclonal antibodies for treatment of CD70+ EBV+ B-cell lymphomas. Using two Burkitt's lymphoma lines (Raji and Jijoye) that express surface CD70 and a CD70- Burkitt's lymphoma line (Akata), we show that two different monoclonal antibodies directed against human CD70 allow rabbit and human complement to kill EBV+ B cells in a CD70-dependent manner in vitro. In the absence of complement, neither anti-CD70 antibody induced in vitro killing of CD70+ cell lines. Importantly, i.p. injection of anti-CD70 antibodies also inhibited the growth of CD70+ Burkitt's lymphoma cells in severe combined immunodeficient mice but did not inhibit the growth of CD70- Burkitt's lymphoma cells. These results suggest that anti-CD70 antibodies may be useful for the treatment of CD70+ B-cell lymphomas.

AB - A monoclonal antibody (Rituximab) directed against the B-cell surface antigen, CD20, is increasingly used as a therapy for B-cell lymphomas. However, CD20 is expressed on all normal mature B cells and hence is not a specific tumor target. In contrast, CD70 is expressed on highly activated lymphocytes as well as on many B-cell and T-cell lymphomas but is not expressed on the great majority of B cells and T cells. In this report, we have explored the potential utility of anti-CD70 monoclonal antibodies for treatment of CD70+ EBV+ B-cell lymphomas. Using two Burkitt's lymphoma lines (Raji and Jijoye) that express surface CD70 and a CD70- Burkitt's lymphoma line (Akata), we show that two different monoclonal antibodies directed against human CD70 allow rabbit and human complement to kill EBV+ B cells in a CD70-dependent manner in vitro. In the absence of complement, neither anti-CD70 antibody induced in vitro killing of CD70+ cell lines. Importantly, i.p. injection of anti-CD70 antibodies also inhibited the growth of CD70+ Burkitt's lymphoma cells in severe combined immunodeficient mice but did not inhibit the growth of CD70- Burkitt's lymphoma cells. These results suggest that anti-CD70 antibodies may be useful for the treatment of CD70+ B-cell lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=30344467237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344467237&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0253

DO - 10.1158/1535-7163.MCT-05-0253

M3 - Article

VL - 4

SP - 2037

EP - 2044

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -